Influenza A viruses and SARS-CoV-2 cause global health problems. Establishes factors involved in viral replication, antiviral defence or inflammation are considered attractive targets for pharmaceutical treatment strategies. We will design tailor-made nanoparticles for compounds with limited cell-permeation. We will use an available and highly scalable synthetic antiviral drug, a natural anti-inflammatory drug, or inhibitors for viral uptake and viral uncoating. These nanoparticles will be characterized for their functionality in cellular systems.
Prof. Dr. Christina Ehrhardt
Experimental Virology Section
Institute of Medical Microbiology
University Hospital Jena (UKJ)
Hans-Knöll-Str. 2
07745 Jena
Phone: + 49 3641 9 395 701
Christina.Ehrhardt@med.uni-jena.de
Prof. Dr. Carsten Hoffmann
Institute for Molecular Cell Biology
University Hospital Jena (UKJ)
Hans-Knöll-Str. 2
07745 Jena
Phone: + 49 3641 9 395 600
carsten.Hoffmann@med.uni-jena.de
Dr. Stephanie Schubert
Institute of Pharmacy (IP)
Friedrich Schiller University Jena
Lessingstrasse 8
07743 Jena
Phone: +49 3641 9-48599
stephanie.schubert@uni-jena.de
Laura Klement
Institute for Molecular Cell Biology
University Hospital Jena (UKJ)
Hans-Knöll-Str. 2
07745 Jena
laura.klement@uni-jena.de